α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Tuning the Balance between Fibrillation and Oligomerization of α-Synuclein in the Presence of Dopamine

Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction

α-synuclein strains that cause distinct pathologies differentially inhibit proteasome

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

Chemical disaggregation of alpha-synuclein fibrils as a therapy for synucleinopathies

Alpha-synuclein as therapeutic target in Parkinson's disease

Heparan sulfate proteoglycans mediate prion-like α-synuclein toxicity in Parkinson's in vivo models

Initiation and propagation of α-synuclein aggregation in the nervous system, Molecular Neurodegeneration

p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1

Zeroing in on neurodegenerative α-synuclein

Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice - Aniszewska - 2022 - Brain and Behavior - Wiley Online Library